Reference : The future of obesity: new drugs versus lifestyle interventions.
Scientific journals : Article
Human health sciences : Pharmacy, pharmacology & toxicology
Human health sciences : Endocrinology, metabolism & nutrition
The future of obesity: new drugs versus lifestyle interventions.
Scheen, André mailto [Université de Liège - ULiège > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques - Médecine interne générale >]
Expert Opinion on Investigational Drugs
Ashley Publications Ltd
Yes (verified by ORBi)
United Kingdom
[en] Anti-Obesity Agents/administration & dosage/therapeutic use ; Drug Design ; Exercise Therapy ; Humans ; Life Style ; Obesity/diet therapy/drug therapy
[en] BACKGROUND: Obesity causes serious medical complications and impairs quality of life. However, its management remains challenging. OBJECTIVE: To assist health professionals who counsel patients who are overweight or obese by discussing the possible add-on value of new drugs over lifestyle interventions. METHODS: A critical analysis is made of the available evidence of the long-term efficacy of diet and exercise and/or anti-obesity agents such as orlistat, sibutramine and rimonabant. RESULTS/CONCLUSION: Lifestyle interventions remain the cornerstone of the treatment of obesity, but adherence is poor and long-term success is modest. Pharmacological agents may be useful adjuncts for improving weight loss and maintenance, and health outcomes, and should be continued in good responders. Drug therapy and lifestyle intervention are not opponent strategies, but should probably be combined to tackle obesity.
Researchers ; Professionals ; Students

File(s) associated to this reference

Fulltext file(s):

Open access
Editorial Exp Opin Invest Drugs Future of obesity 2008.pdfAuthor postprint48.02 kBView/Open

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.